BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 09-Nov-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2020 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.

ORIONPHARM 13-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 1.17 for July-September 2019 as against Tk. 0.98 for July-September 2018; Consolidated NOCFPS was Tk. 1.96 for July-September 2019 as against Tk. 2.62 for July-September 2018. Consolidated NAV per share (including revaluation surplus) was Tk. 76.33 as on September 30, 2019 and Tk. 75.19 as on June 30, 2019. Consolidated NAV per share (excluding revaluation surplus) was Tk. 68.15 as on September 30, 2019 and Tk. 66.98 as on June 30, 2019.

ORIONPHARM 05-Nov-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2019 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.

ORIONPHARM 15-Nov-2018

(Q1 Un-audited): Consolidated EPS was Tk. 0.98 for July-September, 2018 as against Tk. 1.10 for July-September, 2017; Consolidated NOCFPS was Tk. 2.62 for July-September, 2018 as against Tk. 2.53 for July-September, 2017. Consolidated NAV per share (including revaluation surplus) was Tk. 73.65 as on September 30, 2018 and Tk. 72.05 as on September 30, 2017. Consolidated NAV per share (excluding revaluation surplus) was Tk. 65.35 as on September 30, 2018 and Tk. 63.62 as on September 30, 2017.

ORIONPHARM 11-Nov-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2018 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.

ORIONPHARM 15-Nov-2017

(Q1 Un-audited): Consolidated EPS was Tk. 1.10 for July-September, 2017 as against Tk. 1.17 for July-September, 2016; Consolidated NOCFPS was Tk. 2.53 for July-September, 2017 as against Tk. 1.33 for July-September, 2016. Consolidated NAV per share (including revaluation surplus) was Tk. 72.05 as on September 30, 2017 and Tk. 71.09 as on September 30, 2016. Consolidated NAV per share (excluding revaluation surplus) was Tk. 63.62 as on September 30, 2017 and Tk. 62.51 as on September 30, 2016.

ORIONPHARM 08-Nov-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2017 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2017.

ORIONPHARM 15-Nov-2016

(Q1 Un-audited): Consolidated EPS was Tk. 1.17 for July-September, 2016 as against Tk. 0.73 for July-September, 2015; Consolidated NOCFPS was Tk. 1.33 for July-September, 2016 as against Tk. 1.08 for July-September, 2015. Consolidated NAV per share was Tk. 71.09 as of September 30, 2016 and Tk. 69.48 as of September 30, 2015.

ORIONPHARM 07-Nov-2016

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2016 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2016.

ORIONPHARM 17-May-2015

(Q1 Un-audited): Consolidated Net Profit after tax (excluding non controlling interest) from Jan'15 to March'15 was Tk. 330.26 million with consolidated EPS of Tk. 1.41 as against Tk. 380.80 million and Tk. 1.63 respectively for the same period of the previous year.

Previous Next page